Back to Search
Start Over
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
- Source :
- Leukemia Research. 74:86-88
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- NA
- Subjects :
- Male
Oncology
Cancer Research
Ruxolitinib
medicine.medical_specialty
Time Factors
ruxolitinib,myelofibrosis, spleen
Socio-culturale
Spleen
03 medical and health sciences
0302 clinical medicine
Hematology
Internal medicine
80 and over
medicine
Humans
Myelofibrosis
Aged
business.industry
Aged, 80 and over
Female
Middle Aged
Organ Size
Rituximab
Primary Myelofibrosis
medicine.disease
medicine.anatomical_structure
030220 oncology & carcinogenesis
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 01452126
- Volume :
- 74
- Database :
- OpenAIRE
- Journal :
- Leukemia Research
- Accession number :
- edsair.doi.dedup.....df41d59f35e72944e8125e7c28b563c8
- Full Text :
- https://doi.org/10.1016/j.leukres.2018.10.001